AU2017345390B2 - Use of itolizumab to reduce phosphorylation of CD6 - Google Patents
Use of itolizumab to reduce phosphorylation of CD6 Download PDFInfo
- Publication number
- AU2017345390B2 AU2017345390B2 AU2017345390A AU2017345390A AU2017345390B2 AU 2017345390 B2 AU2017345390 B2 AU 2017345390B2 AU 2017345390 A AU2017345390 A AU 2017345390A AU 2017345390 A AU2017345390 A AU 2017345390A AU 2017345390 B2 AU2017345390 B2 AU 2017345390B2
- Authority
- AU
- Australia
- Prior art keywords
- ser
- leu
- val
- thr
- itolizumab
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Physical Education & Sports Medicine (AREA)
- Transplantation (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Electrochromic Elements, Electrophoresis, Or Variable Reflection Or Absorption Elements (AREA)
- Ultra Sonic Daignosis Equipment (AREA)
- Electrically Operated Instructional Devices (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN201641035602 | 2016-10-18 | ||
| IN201641035602 | 2016-10-18 | ||
| PCT/IB2017/056403 WO2018073721A1 (en) | 2016-10-18 | 2017-10-16 | Use of itolizumab to reduce phosphorylation of cd6 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2017345390A1 AU2017345390A1 (en) | 2019-05-02 |
| AU2017345390B2 true AU2017345390B2 (en) | 2024-08-08 |
Family
ID=62019244
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2017345390A Active AU2017345390B2 (en) | 2016-10-18 | 2017-10-16 | Use of itolizumab to reduce phosphorylation of CD6 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US20190248913A1 (cg-RX-API-DMAC10.html) |
| EP (1) | EP3528846A4 (cg-RX-API-DMAC10.html) |
| JP (1) | JP7065085B2 (cg-RX-API-DMAC10.html) |
| KR (1) | KR102469798B1 (cg-RX-API-DMAC10.html) |
| AU (1) | AU2017345390B2 (cg-RX-API-DMAC10.html) |
| CA (1) | CA3076861A1 (cg-RX-API-DMAC10.html) |
| IL (1) | IL266087B2 (cg-RX-API-DMAC10.html) |
| WO (1) | WO2018073721A1 (cg-RX-API-DMAC10.html) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT2993186T (pt) | 2008-03-14 | 2019-11-29 | Biocon Ltd | Anticorpo monoclonal e um método do mesmo |
| US10189899B2 (en) | 2013-07-23 | 2019-01-29 | Biocon Limited | Use of a CD6 binding partner and method based thereon |
| KR102514528B1 (ko) | 2016-10-21 | 2023-03-27 | 바이오콘 리미티드 | 루푸스 치료를 위한 단일클론항체 및 이의 치료방법 |
| WO2019169015A1 (en) * | 2018-02-27 | 2019-09-06 | Equillium, Inc. | Anti cd6 antibodies for treating severe asthma |
| US20230076643A1 (en) * | 2019-12-30 | 2023-03-09 | City Of Hope | Methods of making and using regulatory t cells and effector t cells having chimeric antigen receptors targeted to cd6, cd19, and/or an il-13r for treatment of autoimmune disorders and cancers |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT2993186T (pt) * | 2008-03-14 | 2019-11-29 | Biocon Ltd | Anticorpo monoclonal e um método do mesmo |
| US10189899B2 (en) * | 2013-07-23 | 2019-01-29 | Biocon Limited | Use of a CD6 binding partner and method based thereon |
| KR102514528B1 (ko) * | 2016-10-21 | 2023-03-27 | 바이오콘 리미티드 | 루푸스 치료를 위한 단일클론항체 및 이의 치료방법 |
| US20230151107A1 (en) * | 2020-04-04 | 2023-05-18 | Biocon Limited | Anti-cd6 antibody compositions and methods for treating and reducing negative effects of a coronavirus including covid-19 |
-
2017
- 2017-10-16 IL IL266087A patent/IL266087B2/en unknown
- 2017-10-16 EP EP17862860.8A patent/EP3528846A4/en active Pending
- 2017-10-16 CA CA3076861A patent/CA3076861A1/en active Pending
- 2017-10-16 AU AU2017345390A patent/AU2017345390B2/en active Active
- 2017-10-16 KR KR1020197014350A patent/KR102469798B1/ko active Active
- 2017-10-16 JP JP2019520731A patent/JP7065085B2/ja not_active Expired - Fee Related
- 2017-10-16 WO PCT/IB2017/056403 patent/WO2018073721A1/en not_active Ceased
-
2019
- 2019-04-17 US US16/387,442 patent/US20190248913A1/en not_active Abandoned
-
2023
- 2023-06-15 US US18/335,542 patent/US20240101700A1/en active Pending
Non-Patent Citations (3)
| Title |
|---|
| A IRA ET AL.: "Immunological and histological evaluation of clinical samples from psoriasis patients treated with anti- CD 6 itolizumab", MABS, vol. 6, no. 3, 1 May 2014 (2014-05-01), pages 782 - 792, XP055478453 * |
| Krupashankar et al., Efficacy and safety of itolizumab, a novel anti-CD6 monoclonal antibody, in patients with moderate to severe chronic plaque psoriasis: results of a double-blind, randomized, placebo-controlled, phase-III study,2014. * |
| Rodriguez, P. C et al., A clinical exploratory study with itolizumab, an anti-CD6 monoclonal antibody, in patients with rheumatoid arthritis, Results in Immunology, Volume 2, 2012, Pages 204-211 * |
Also Published As
| Publication number | Publication date |
|---|---|
| KR102469798B1 (ko) | 2022-11-22 |
| KR20190070957A (ko) | 2019-06-21 |
| EP3528846A1 (en) | 2019-08-28 |
| EP3528846A4 (en) | 2020-06-03 |
| US20190248913A1 (en) | 2019-08-15 |
| WO2018073721A1 (en) | 2018-04-26 |
| AU2017345390A1 (en) | 2019-05-02 |
| IL266087B1 (en) | 2023-10-01 |
| IL266087B2 (en) | 2024-02-01 |
| US20240101700A1 (en) | 2024-03-28 |
| JP2020504597A (ja) | 2020-02-13 |
| JP7065085B2 (ja) | 2022-05-11 |
| IL266087A (en) | 2019-06-30 |
| CA3076861A1 (en) | 2018-04-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20240101700A1 (en) | Use of itolizumab to reduce phosphorylation of cd6 | |
| US20220193199A1 (en) | Il-15 and il-15ralpha sushi domain based modulokines | |
| JP2022091985A (ja) | 組合せ医薬組成物 | |
| JP4938957B2 (ja) | Cd30またはcd30lのアンタゴニストを使用する自己免疫および慢性炎症性状態の処置法 | |
| KR102040235B1 (ko) | RGMa 결합 단백질 및 그 사용 | |
| US11547741B2 (en) | Methods of use of soluble CD24 for treating immune related adverse events in cancer therapies | |
| Bloemendaal et al. | Anti–tumor necrosis factor with a glyco-engineered Fc-region has increased efficacy in mice with colitis | |
| KR20230015348A (ko) | Th2 개재성 질환을 치료 또는 예방하기 위한 PD-1 작용제 함유 의약 조성물 | |
| RU2832188C2 (ru) | Дозировка и схема введения для лечения или предупреждения связанных с с5 заболеваний посредством применения антитела против с5 кровалимаба | |
| RU2817602C2 (ru) | Молекулы антител, которые связывают cd137 и ox40 | |
| HK40072257A (en) | A PHARMACEUTICAL COMBINATION COMPRISING A BIFUNCTIONAL IMMUNE CHECKPOINT/TGFβ INHIBITOR | |
| HK40074884A (en) | Il-15 and il-15ralpha sushi domain based on modulokines | |
| HK40004449A (en) | Il-15 and il-15raplha sushi domain based modulokines | |
| HK40024980A (en) | Methods of use of soluble cd24 for treating immune related adverse events in cancer therapies | |
| HK40004449B (en) | Il-15 and il-15ralpha sushi domain based modulokines | |
| Levin et al. | Therapeutic efficacy of anti-TNF is mediated via Fcγ-receptors and Fc glyco-engineering increases therapeutic potency |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) |